CONFERENCE MEDIA ANALYSIS January 2018

1 CONFERENCE MEDIA ANALYSIS | January 6 - 16, 2018

3 Report Objective & Methodology

4 Executive Summary

7 Conference Media Analysis

News Media Performance

Social Media Performance

News Media Coverage by Topic

Spotlight on Neuroscience

Other Notable Conference Themes

12 Merck at JPM18 Overview

News Media Performance

Social Media Performance

Quality of Coverage

Influencers

17 Methodology Detail

2 CONFERENCE MEDIA ANALYSIS | January 6 - 16, 2018

Preface

J.P. Morgan held its 36th Annual Healthcare Conference (the “Conference or JPM18”) on January 8-11, 2018. Cision, and its analytics and information services division, Cision Intelligence, sought to understand the major media stories generated during the conference, the volume and quality of news and social media related to those storylines, and the companies and speakers producing the greatest media reach and engagement. This report is an independent research initiative completed by Cision, based solely on its software-based monitoring of broadcast, online, and social media where stories, companies, and speakers participating in the conference were identified. Although no participant, nor J.P. Morgan sponsored nor endorsed this work, we showcased Merck to highlight a deeper company-specific review. Cision retains all rights to this material.

Scope & Methodology

Although the Conference was held January 8-11, we monitored broadcast and online news, as well as social media from January 6-16, 2018. We filtered the monitoring to approximately 120 major national, regional, and investor-focused outlets. And, because Twitter was the most dominant social channel, we excluded activity on other social platforms as non-material. We monitored media activity for 22 pharmaceutical companies, yet limited the report analysis to nine (9) companies with the greatest activity, namely Allergan, Celgene, Eli Lilly, GSK, J&J, Merck, Pfizer, Sanofi, and Teva.

For each relevant story and company, we human-scored multiple attributes as quantitative proxies for quality, such as sentiment/tone (on a proprietary 7-point scale from very negative to very positive), prominence within the article, quoted executives, references to innovation, and references to financial announcements or commentary.

The team assembled the raw data to then understand comparative story count volumes; audience reach (actual views based on advanced machine learning algorithms); social volume and news article engagement on social media; the most influential journalists and outlets based on reach and end-reader engagement; and share-of-voice (SOV) across many of these metrics and story quality attributes, such as tone.

Lastly, we highlight our Quality Score, a weighted brand reputation index that reflects a weighted score across relevant story attributes; the higher the Quality Score, the more impactful the story. See slide 18 for additional information about our methodology. 3 CONFERENCE MEDIA ANALYSIS | January 6 - 16, 2018

Executive Summary – JPM18 Highlights

Major Story Lines

• Tax Reform was a timely and significant theme for the meeting. Coverage emphasized that the new policy is good for the pharmaceutical business, while other coverage questioned whether it’s good for patients. • In advance of the conference, Pfizer’s exit from Alzheimer’s/Parkinson’s R&D was widely covered, and media followed up with other industry leaders to get their perspectives. Overall, the industry is portrayed as remaining committed to research in that area moving forward. • Drug Pricing was discussed in coverage about tax reform, but also in coverage of competitiveness in the pharma industry, and interviews with pharma executives. • Other themes included gender inequity in the pharmaceutical industry, the need for industry disruption, and Bill Gates’ keynote.

4 CONFERENCE MEDIA ANALYSIS | January 6 - 16, 2018

Executive Summary - Competitive Performance

Share of Story Count Share of Social Posts Share of News Engagement

• J&J led share of voice in news and social mentions overall, though saw the lowest share of stories with a primary focus during the conference. Much of the social conversation was driven by owned content. • Pfizer led among stories with a primary focus and saw the highest number of news story shares to social media, though this was largely due to a high percentage of negative coverage. • GSK and Celgene followed Pfizer in terms of primary coverage, respectively, though GSK’s primary coverage was far more favorable than Celgene’s. Celgene followed J&J in social post volume. • Merck ranked 6th among companies tracked at JPM18 in terms of story count overall, 7th for stories with a primary focus, and 5th in social media content.

5 CONFERENCE MEDIA ANALYSIS | January 6 - 16, 2018

Executive Summary – Daily News + Social Drivers

Story Count by Day GSK: Considering Buying Pfizer’s Consumer Celgene: Impact $7B Business Acquisition Allergan: Financial Forecast Merck: Thought Leadership Pfizer: Pulling Out of on Drug Pricing, Alzheimer’s Alzheimer’s/Parkinso n’s Teva: Executive Salary Cuts, and Layoffs

Post Count by Day Pfizer: Announcement J&J: of New Genetic Celgene: #ChampionsOfScien Sequencing ce RTs Intent to Consortium Acquire Merck: Maria Bartiromo/Fox Impact Business Interview with CEO Biomedicines Ken Frazier Eli Lilly: Surpassed Merck in Revenue; Diabetes Pricing

6 CONFERENCE MEDIA ANALYSIS | January 6 - 16, 2018

Competitive News Media Performance Story Volume Comparison Prominence Mix Tone Mix

Story Share of Company Audience % Primary % Pos % Neg Share Eng Highlights Count JPM18*

Merck CEO Kenneth Frazier commenting on the tax overhaul’s impact on Merck 70 3.6M 11% 83% 0% 6K 10% the pharmaceutical industry, drug pricing, and Alzheimer’s research drove coverage.

GSK’s interest in purchasing Pfizer’s Consumer Business and pulling out Pfizer 114 5.9M 49% 59% 30% 193K 16% of Alzheimer’s research contributed to a peak in coverage on January 8 and 9.

CEO Brent Saunders touted the company’s booming Botox business and Allergan 44 1.6M 27% 73% 5% 174K 9% discussed the company’s 2018 financial forecast during JPM18.

Bloomberg and CNBC interviewed Eli Lilly CEO David Ricks on drug Eli Lilly 86 4.5M 12% 77% 4% 12K 12% pricing and diabetes treatments. Interest in purchasing Pfizer’s Consumer Business and the CEO GSK 85 3.1M 44% 78% 0% 15K 12% reshuffling 40% of the management team led GSK coverage.

On January 8, CEO Alex Gorsky stated that J&J should be worried about J&J 125 4.9M 4% 80% 1% 179K 20% Amazon disrupting their business.

Sanofi and Alnylam restructuring their deal for Alnylam’s pipeline drugs Sanofi 30 648K 20% 50% 7% 4K 4% drove coverage throughout the conference.

Teva’s Board of Directors cutting their salaries in half and eliminating 40 Teva 44 1.3M 68% 7% 9% 2K 9% manufacturing sites drove coverage on January 10. 7 Celgene’s intent to acquire Impact Biomedicines generated a peak in 7 Celgene 111 4.3M 32% 71% 15% 5K 16% coverage on the first day of the conference. *JPM18 = 705 stories captured from top tier media list CONFERENCE MEDIA ANALYSIS | January 6 - 16, 2018

Competitive Social Media Performance Twitter Volume Comparison Tone Mix Engagement by Day

Unique Potential Share of Company Post Count % RT Post Eng Highlights Authors Reach JPM18*

Merck’s social media conversation and engagement were in large part driven by Merck 292 78% 228 1.1K 3.1M 1% owned content and Fox/CNBC promotions of scheduled interviews with Ken Frazier. Regeneron announced a new genetic sequencing consortium in which Pfizer has Pfizer 325 67% 257 740 3.3M 1% been tabbed as a partner and will co-fund the work with a planned completion by 2022. Statements made by Brent Saunders on drug pricing and the strength of Botox’s Allergan 201 60% 148 522 1.4M 1% performance were positively received. He was the driving force behind over half of Allergan’s social media content. Dave Ricks’s discussion of drug pricing, tax reform, and more with Meg Tirrell of Eli Lilly 189 72% 131 464 2.3M 1% CNBC was prominently discussed. His comments on drug pricing were met with some criticism, particularly for Diabetes. Emma Walmsley shared her thoughts on being the first female CEO to lead a major GSK 273 82% 206 731 2.8M 1% pharmaceutical company in an interview with Meg Tirrell, and in widely shared pieces from STAT and Business Insider. J&J led in total posts, largely due to owned content launched throughout the event. J&J 1,138 82% 587 2.9K 10.7M 4% J&J shared 41 #ChampionsOfScience posts (a series on innovation and advancement) garnering nearly 500 retweets. The announcement that Sanofi and Alnylam will restructure their rare disease Sanofi 319 55% 213 519 2.6M 1% alliance drove the social conversation, with most of the focus on Alnylam re- acquiring the rights to patisiran. The “Teva Turnaround” was a prominent theme due to discussion of Kåre Schultz Teva 123 46% 93 142 500K 0% comments on past mistakes and plans to cut over 14,000 jobs and cut back $3B in spend in a large scale restructure. Celgene’s acquisition of Impact Biomedicines for $1.1B (up to $7B) accounted for 8 Celgene 560 68% 375 1,5K 5.2M 2% over 25% of their key metrics. The deal saw a mixed reception on social media, with 8 some feeling Celgene overpaid. *JPM18 = 31,683 Twitter posts CONFERENCE MEDIA ANALYSIS | January 6 - 16, 2018

Competitive Coverage by Topic Industry Core Topics

Spotlight on Executives Spotlight on Financials Spotlight on Innovation

• Merck saw the most original coverage of executives • Celgene saw the most financial-oriented coverage • Pfizer saw the most coverage with an “innovation” among competitors. CFO Robert Davis stating the following the announcement they plan to purchase theme, however this coverage was largely negative, company will continue to seek smaller acquisitions Impact Biomedicines, the release of their Q4 with coverage focusing on their announcement and CEO Kenneth Frazier’s interviews led to their earnings, and shares falling after their 2018 revenue they are ending research into new Alzheimer’s and lead in executive visibility during JPM18. forecast was short of analysts’ expectations. Parkinson’s drugs.

• Eli Lilly followed Merck largely due to Reuters • GSK’s announcing they’re looking into purchasing • Eli Lilly and J&J’s innovation-focused coverage coverage of CEO Dave Ricks stating the company’s Pfizer’s Consumer Business drove financial coverage referenced their respective histories in Alzheimer’s cash would be used for business development for Pfizer and GSK alike. research in a widely syndicated Reuters story about opportunities, including early-stage M&A. Pfizer. • Merck’s financials were referenced frequently in • GSK’s CEO Emma Walmsley was interviewed on coverage of CEO Kenneth Frazier’s comments on • Celgene CEO Mark Alles commented on the potentially buying Pfizer’s consumer business, the impact of tax reform and Amazon’s potential purchase of Impact Biomedicines in their gender diversity, and shaking up the company’s disruption to the distribution of drugs. innovation coverage. Merck CEO Kenneth Frazier leadership in television and print interviews. discussed how tax reform will spark innovation in • Allergan, Sanofi, and J&J received little financial the future for pharmaceutical companies. • Pfizer and Sanofi’s lack of television interviews with coverage. its executive leadership contributed to relatively • Teva and Allergan saw no innovation-focused low executive visibility. coverage. 9 CONFERENCE MEDIA ANALYSIS | January 6 - 16, 2018

Spotlight on Neuroscience News and Social SOV • Neuroscience emerged as a theme at JPM18 among key competitors, with 39 stories and 146 social media posts. • Pfizer led the industry in Neuroscience news coverage from the conference, though 100% was negative. • Heading into the conference, news that Pfizer planned to end its Alzheimer’s and Parkinson’s R&D program was widely covered in the new.. A Reuters piece with roughly 20 pickups was primarily focused on Pfizer, but also mentioned Eli Lilly and GSK for their involvement in the Dementia Discovery Fund, as well as J&J for its partnership with Pfizer in an unsuccessful clinical trail. Stories by Week • Negative coverage continued on the first day of the conference, including a scathing opinion piece by Michael Hiltzik for the Los Angeles Times in which he criticizes Pfizer for cutting this program while pocketing money from the new corporate tax cuts. • The social media conversation around Pfizer from the conference was largely focused on this topic as well. Andy Lee (@andy_d_lee) of NeuroInitiative suggested Pfizer Neuro experts looking for a new job apply to his Parkinson’s program. Taking a more positive tone, @BioWorld and @pharmaphorum each noted Pfizer’s plan to assist research through a venture fund instead. • J&J saw the most neuroscience related social media content, though largely due to retweets of their owned posts. Prominence of Coverage Tone of Coverage • The most successful posts from the @JNJInnovation handle discussed their 15 new collaborations, and the potential use of AI to analyze speech patterns of Alzheimer’s patients in an effort to detect the disease earlier. • J&J Alzheimer’s R&D was mentioned in reporting on Pfizer’s end to its own program, but did not see any primary coverage. A piece carried in the Wall Street Journal and Fox Business discussing industry efforts to fight Alzheimer’s in spite of recent setbacks made reference to J&J’s research collaboration with the University of Pennsylvania, as well as initiatives from Eli Lilly, Merck, Takeda, and Roche. • Merck is mentioned in Pfizer coverage as a company that will continue to invest in Alzheimer’s and Parkinson’s R&D. 10 CONFERENCE MEDIA ANALYSIS | January 6 - 16, 2018

Other Notable Conference Themes

• Bill Gates’ keynote address at JPM18 received widespread praise and social coverage: • Social media conversations praised Gates’ emphasis on impact over earnings, although he was careful to note that impact and earnings are not mutually exclusive. Many posts featured excerpts from his speech, highlighting the theme of working together to improve the health and well-being of the world, instead of viewing health as a zero sum game. • His speech elicited 11 news stories, many of which noted Gates’ message to drug makers that the private sector can benefit from pursuing breakthroughs in global health. • Pictures of attendees and presenters wearing Pink Socks and using the #pinksocks saw 1,000 social posts: • “Pink Socks,” a movement started by Nick Adkins of ReelDX, were worn, pictured, and mentioned in social posts throughout the conference. The socks are meant to represent what many people believe is an urgent need for disrupting healthcare from the ground up. • JPM’s “Michael Problem” was a consistent criticism of the conference: • While largely ignored in news media (with a few exceptions), the fact that more men named Michael than female CEOs gave presentations at the J.P. Morgan Healthcare Conference drew critical social posts from users who dubbed the phenomenon the “Michael Problem.” • In addition to pointing out the Michael Problem, social posts dove further into the issue of gender inequality, pointing out that men represented more than 75% of the JPM18 speakers overall and the pharmaceutical industry has a gender inclusion problem among its executive leadership.

11 CONFERENCE MEDIA ANALYSIS | January 6 - 16, 2018

Merck at JPM18 – News Media Performance Story Count and Engagement • Merck saw 70 stories over the course of JPM18. This ranked 6th among major pharma companies tracked. • With nearly three quarters of coverage being passing mentions, coverage was also overwhelmingly neutral. • Among stories with a primary or secondary focus, 79% was positive. • 66% of stories mentioned a Merck executive, 53% referenced financials, and 16% of stories discussed Merck innovation. • Substantive coverage was largely driven by interviews with Stories and Engagement by Day Merck executives: • Interviews of CEO Ken Frazier featured his outlook on the company’s future, noting that the Trump administration’s tax reform agenda helps Merck compete better with ex-US competitors and has been been helpful for patients accessing affordable drugs. In particular, his interview with Maria Bartiromo covered these themes, as well as the “Amazon effect” and the increasing incidence of Alzheimer’s. • Merck was also mentioned in coverage of Pfizer’s exit from Alzheimer’s research and development. Merck R&D chief Roger Perlmutter said in an interview that they understand the space is particularly challenging, but the company believes it is important to “remain in the game.” Prominence of Coverage Tone of Coverage • Passing mentions focused on: • Industry-oriented coverage of tax reform, which often asserted that the changes are positive for pharma and that not much will change in the short term as far as research and development. • Other coverage reported that executives are expecting M&A activity could pick up on the heels of tax reform passing, as already evident by Celgene’s agreement to purchase Impact Biosciences. The article references that M&A’s on a large scale such as Merck’s acquisition of Schering Plough in 2009 had become rare, but implies this may change.

12 CONFERENCE MEDIA ANALYSIS | January 6 - 16, 2018

Merck at JPM18 – Social Media Performance Conference and Merck Post Volume YOY Merck JPM by Engagement YOY • Merck JPM18 Twitter volume remained consistent YOY, with 292 in 2018 making up 3% of all Merck Twitter content during the review period and 1% of all JPM18 posts. • However, post engagement, potential reach, and tone all saw positive gains in 2018. • Unique author count also increased from 192 to 248, which expanded the base for engagement and potential reach. • Engagement more than doubled in 2018 to 1,093. This was primarily due to additional posts from Merck’s Twitter handle, and posts from prominent authors such as Maria Bartiromo. The large following (comparatively) for Merck JPM Posts by Tone YOY Post Volume by Engagement Value each contributed to above average engagement per post. Competitors saw a similar trend of prominent media anchors (in several cases, the same ones)/pharma news outlets driving engagement, or content creation through owned channels. • Merck authored content used positive language such as: “excited to be at,” “continued innovation,” and “improving global health.” Retweets of this content carried much of the positive coverage for the brand. • Excluding owned content, only 60 original tweets were created mentioning the Merck brand. Of those, only a handful were organic consumer commentary. The vast majority of coverage consisted of interview promotion, content recap/transcripts, or links to larger articles covering key topics (rebates, pricing, tax reform implications) discussed by Merck JPM18 Posts and Engagement by Day Merck CEO Ken Frazier. • Event related posts only represented 3% of total Merck mentions during the reporting period, however they peaked at 14% on the 8th and 9th. This did contribute to a minor uptick in overall daily brand volumes, but as a point of comparison, a single stock/market tweet generated more volume (660 retweets) about the brand than the JPM18 contribution.

13 CONFERENCE MEDIA ANALYSIS | January 6 - 16, 2018

Merck Quality Score

• The average Quality Score for Merck during JPM18 was 25. • 4% of coverage had a high quality score of 40+. • No stories had a negative QS. • Stories with the highest QS included: • Tax Plan Puts American Companies On An Even Playing Field: Merck CEO (Fox Business) 01/09/18, QS:45.0 Topics: Positive, Merck Executive, Merck Innovation • Amazon Could Be Helpful To Us: Merck CEO (Fox Business) 01/09/18, QS:45.0 Topics: Positive, Merck Executive, Merck Innovation • Merck CEO Interview (Fox Business Mornings With Maria) 01/09/18, QS:45.0 Topics: Positive, Merck Executive, Merck Innovation • Stories with the lowest QS did not have any common themes: • Friday Five - The JP Morgan Debrief (FirstWordPharma) 01/11/17, QS: 25.0 Tags: Neutral, Merck Executive • The Health 202: Here's One Legal and Political Battle You Didn't Expect (Washington Post) 01/10/17, QS: 20.0 Tags: Neutral, Merck • Biotech ETF Leaks Cash As Hopes For More M&A Fizzle (Bloomberg News) 01/16/18, QS:25.0 Tags: Neutral, Merck Executive 14

*See page 18 for definitions/methodology for Quality Score. CONFERENCE MEDIA ANALYSIS | January 6 - 16, 2018

Merck Influencers: Top Outlets & Social Authors News Media Top Sources Social Media Top Authors

Interviews with Ken Frazier drove primary coverage in the top 10 Top twitter authors primarily consisted of CNBC/FOX affiliates, sources with the most engagement. financial advisors, news and journalist handles. • Fox Business was the leading source in terms of engagement, with a • Two authors tweeted about Merck coverage YOY: Brecht Vanneste (Self combined 2,264 shares during the review period. Maria Bartiromo’s proclaimed “active in the pharmaceutical industry”), and Jodi Gralnick (CNBC interview with Ken Frazier drove this coverage, with additional reporting producer). While both garnered enough likes and retweets to push engagement, focused on his statements about Alzheimer’s, Amazon drug sales, and the their potential unique audience was low. US tax overhaul. • Tweets from Fox Business News’ Maria Bartiromo generated the most • Bartiromo’s interview with Frazier was also cited by CNBC, another top engagement, despite only posting twice. In promotion of JPM18 coverage, she source, as a highlight of the conference. A separate Frazier interview shared a lineup of speakers/participants, which included “@Merck ceo.” conducted by CNBC’s Meg Tirrell was the primary driver of coverage from • Vista Partners, live tweeted from the event to present its services. They shared this source. Along with the interview itself, CNBC posted additional coverage and quotes from the event, helping consumers ‘stay informed.’ Despite reporting which focused on Frazier’s comments on drug rebates, as well as a follower base of 52K, and series of 4 posts, few users interacted with the his praise of the US tax plan for allowing Merck to invest more heavily in content (2.75 avg. eng/post). R&D. • FiercePharma shared their “need to know” JPM18 round up article, and • FiercePharma covered Frazier’s statements on drug pricing during a Q&A commentary on drug pricing from a Q&A session with CEO Ken Frazier. session. 15 CONFERENCE MEDIA ANALYSIS | January 6 - 16, 2018

Interactive Dashboards

Analytics Dashboards

• JP Morgan Healthcare 2018 Conference: Merck • JP Morgan Healthcare 2018 Conference: Competitive View

16 CONFERENCE MEDIA ANALYSIS | January 6 - 16, 2018

Scoring Methodology

Source Capture & Filtering Tonality Details Stories are scored on a 7-point tonality scale. Analysts follow a Sources: 120+ top tier sources disciplined methodology for scoring tonality unless other client direction is provided. Media Type: Online sites, newspapers, magazines, broadcast (radio & television) VERY POSITIVE: Includes articles containing positive commentary above and beyond typical positive reporting. This could include, Scoring raving endorsements, references to superlatives (e.g., “best product on the market”), reporting that something is breaking records or is Method: Human-scored unprecedented.

Tonality: 7-point scale POSITIVE: Includes proactive announcements without detracting Prominence: Primary, secondary, mention commentary. Or other articles that have only positive commentary.

SOMEWHAT POSITIVE: Includes articles about a positive topic that Measures has limited detracting commentary, or an article that is primarily neutral but includes one or two references to something positive. Audience: Audience Reached NEUTRAL: Passing mentions or other instances where there is not Story Count: Article in print, online, or broadcast enough context to determine if the story is positive or negative. segment; each wire pickup counts as a Stories in which positive/negative tonality elements balance each separate story other out.

Prominence Details SOMEWHAT NEGATIVE: Includes factual stories about a negative Prominence of a topic falls into one of the following categories: issue if the company is not at fault, or a negative story with some commentary to offset the inherent negativity of an issue. Or an PRIMARY: The topic was the focus of the coverage. article that is primarily neutral but includes one or two references to something negative. SECONDARY: The topic is not the primary focus of the coverage but was heavily mentioned. That is, the topic is featured in either NEGATIVE: Includes articles about a negative issue without an essential (albeit secondary) way or several times throughout redeeming/balancing elements. the story. VERY NEGATIVE: Includes articles containing negative commentary MENTION: The topic is only casually referenced in the coverage, above and beyond typical negative reporting. This could include rather than being of primary or secondary focus. stories containing rants or extremely negative statements. 17 CONFERENCE MEDIA ANALYSIS | January 6 - 16, 2018

Scoring Methodology (cont’d)

The Quality Score* is a single measure that is based on a number of scored article attributes, as outlined below. The Score ranges from -60 to +60. Here is how the score is calculated:

Attribute Description Point System Max. Weight

How prominently the company is mentioned Primary = 15; Secondary = 10; Prominence (e.g., headline, first paragraph) Mention = 5 15

Executive Merck Executive referenced Yes = 5 5

Financials Merck Financials referenced Yes = 5 5

Innovation Merck Innovation referenced Yes = 5 5

Max. Raw Score:30

Attribute Description Point System Max. Weight

Positive/negative score along 7-point scale; +2.0, +1.5, +1.25, +1.0, Tonality neutral obtains 1 multiplier (not zero) -1.25, -1.5, -2.0 +2.0 to -2.0

Max. Story QS: 60

18 *Prototype example of “Quality Score,” a Dow Jones like index, computed as the weighted score of attributes that may have the most impact. CONFERENCE MEDIA ANALYSIS | January 6 - 16, 2018

Scoring Methodology (cont’d) Topics Themes Merck Themes: Executives, Financials, Innovation, Neuroscience Executives Selected when C-suite level official is quoted or interviewed Pfizer Themes: Executives, Financials, Innovation, Neuroscience, Hospira AstraZeneca Themes: Executives, Financials, Innovation, MedImmune Allergan Themes: Executives, Financials, Innovation Financials Selected when financial performance or outlook is AbbVie Themes: Executives, Financials, Innovation, Pharmacyclics discussed Amgen Themes: Executives, Financials, Innovation Bayer Themes: Executives, Financials, Innovation Innovation Selected when pipeline Eli Lilly Themes: Executives, Financials, Innovation, Neuroscience advancements are discussed Gilead Themes: Executives, Financials, Innovation GlaxoSmithKline Themes: Executives, Financials, Innovation, Neuroscience Neuroscience Selected when neuroscience related topics are discussed, Johnson & Johnson Themes: Executives, Financials, Innovation, Neuroscience, Janssen particularly Alzheimer’s or Novartis Themes: Executives, Financials, Innovation, Neuroscience, Alcon, Sandoz Parkinson’s disease. Perrigo Themes: Executives, Financials, Innovation Roche Themes: Executives, Financials, Innovation, Neuroscience, Genentech Sanofi Themes: Executives, Financials, Innovation, Genzyme Takeda Themes: Executives, Financials, Innovation, Neuroscience Teva Themes: Executives, Financials, Innovation Bristol-Myers Squibb Themes: Executives, Financials, Innovation Celgene Themes: Executives, Financials, Innovation Shire Themes: Executives, Financials, Innovation Mylan Themes: Executives, Financials, Innovation

19 CONFERENCE MEDIA ANALYSIS | January 6 - 16, 2018

Scoring Methodology (cont’d) Source Capture & Filtering General Mass Media Healio Dallas Morning News Business Insider WCBS-TV ABC News Kaiser Health News Denver Post CNBC WNBC-TV AFP MedCity News Des Moines Register The Economist WNYW-TV CBS News MedPage Today Detroit Free Press Financial Times KABC-TV CNN Medscape Fort Worth Star Telegram Forbes KNBC-TV Huffington Post medwire News Houston Chronicle Fortune KCBS-TV NBC News Medical Marketing Media Los Angeles Times Investor’s Business Daily KTTV-TV NY Times Modern Healthcare Miami Herald Motley Fool WBBM-TV NPR Pharmaceutical Business Milwaukee Journal Sentinel Reuters WMAQ-TV USA Today Review Minneapolis Star Tribune Wall Street Journal WLS-TV TIME Pharmaceutical Commerce Newark Star-Ledger (nj.com) Seeking Alpha WFLD-TV The AP Pharmaceutical Executive New York Daily News Bloomberg TV KYW-TV Fox News Pharmaceutical New York Post Yahoo Finance WCAU-TV MSNBC Manufacturing Orange County Register WPVI-TV BuzzFeed PharmaLive Orlando Sentinel Public Policy WTXF-TV Yahoo News Pharmaphorum Philadelphia Inquirer The Atlantic KDFW-TV PharmaTimes San Antonio Express-News Daily Beast KTVT-TV Pharmaceutical STAT San Francisco Chronicle Foreign Policy KXAS-TV BioPharma Dive San Jose Mercury News National Journal WFAA-TV Endpoints News Top Regionals Seattle Times Politico FierceBiotech Arizona Republic South Florida Sun-Sentinel Politico Europe FierceHealth Atlanta Journal-Constitution St. Louis Post-Dispatch Roll Call FiercePharma Austin American-Statesman Tampa Bay Times The Hill FiercePharmaManufacturing Boston Globe U-T San Diego Vox FiercePharmaMarketing Charlotte Observer Washington Post FirstWordPharma Chicago Sun-Times Investors Genetic Engineering News Chicago Tribune Barron’s Major Market Local TV HealthDay Cleveland Plain Dealer Bloomberg/ BusinessWeek WABC-TV

20